Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (231-240 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgensWon Kim, Li Zhang, John H Wilton, et al.
Prostate Cancer and Prostatic Diseases|November 6, 2019
Hyperpolarized <sup>13</sup>C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility studyHsin-Yu Chen, Rahul Aggarwal, Robert A Bok, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancerMeenal Sinha, Li Zhang, Sumit Subudhi, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Pageof 37

Showing results (231-240 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgensWon Kim, Li Zhang, John H Wilton, et al.
Prostate Cancer and Prostatic Diseases|November 6, 2019
Hyperpolarized <sup>13</sup>C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility studyHsin-Yu Chen, Rahul Aggarwal, Robert A Bok, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancerMeenal Sinha, Li Zhang, Sumit Subudhi, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Pageof 37